Hollings opens new dedicated cancer clinical trials unit

June 13, 2024

MUSC Hollings Cancer Center has opened the Summer and Clyde Anderson Advanced Cancer Therapy Clinic to provide specialized care to patients participating in phase I clinical trials for cancer. This is Hollings’ first dedicated clinical cancer research unit.

This new clinic space means Hollings will be able to offer patients more and different types of clinical trials that were logistically challenging under the previous arrangement.

Beyond that, it means that future patients will benefit from the specialized clinical expertise of Hollings nursing and physician teams. When the Food and Drug Administration (FDA) approves new treatments, they won’t be new to Hollings team members because they’ll most likely have already administered these new therapies in the years leading up to final FDA drug approval.

Hollings director Raymond N. DuBois, M.D., Ph.D., said this unit showcases Hollings’ commitment to offering the most promising clinical trials.

“Clinical trials are how we improve cancer care for everyone, and quite often, clinical trials are a lifeline for the individual patients who choose to participate,” he said.

The clinic includes everything that could be needed for phase I trials, from areas for infusion to a dedicated nursing team comprised of experienced infusion nurses with specialized training in chemotherapy and immunotherapy infusion and clinical trials’ protocols.

You can read the full article on the MUSC website.